Study drug to boost a hormone system in HFpEF
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This early-phase trial tests a treatment that aims to improve the “natriuretic peptide” hormone system in people with HFpEF (heart failure with preserved pumping strength). It may help reduce symptoms and improve heart and fluid pressure behavior, especially in certain related conditions like kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HFpEF: heart pumping strength (ejection fraction) is 55% or higher
- You have ongoing heart-failure symptoms (NYHA class II to III) and take water pills (diuretics)
- You must not have diabetes and your body mass index (BMI) must be 35 or less
- Your blood pressure must be between 100/60 and 180/100
- Your kidney function must fit one of the trial’s groups: either eGFR 15–80 (with stable diuretics) or eGFR over 50 (with normal resting lung pressures)
- Recent heart, brain, lung, and heart-rhythm problems must not have happened recently, and certain lab values (sodium/potassium/hemoglobin/liver enzymes) must be within safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how matching heart “filling pressure” and heart muscle “energy use” may improve understanding or treatment of HFpEF, a type of heart failure with preserved pumping strength. You may be asked to have heart scans/tests and follow a study plan if your symptoms and test results fit.
This study looks at how the heart muscle works in people with a type of heart failure where the heart pumps normally but doesn't fill properly. It aims to understand the cause better, which could lead to new treatments.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
This study tests a new drug called finerenone to see if it can improve heart function in people with a type of heart failure where the heart pumps normally but is stiff. It may help reduce symptoms and improve quality of life.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.